An ad board in pharma, short for advisory board, is a structured meeting where a pharmaceutical company brings together outside experts to get their input on a specific question the company hasn’t yet answered. These experts are typically physicians, researchers, or patients who offer perspectives the company can’t generate internally. Advisory boards sit at the intersection of medical strategy and compliance, and understanding how they work reveals a lot about how drug companies make decisions.
What Happens at an Advisory Board
A pharmaceutical advisory board is built around a defined question. That might be how to design a clinical trial, how doctors actually prescribe a medication in practice, what unmet needs patients still face, or how to interpret new safety data. The key requirement is that the company is genuinely seeking answers it doesn’t already have. If the company already knows the answer, the meeting risks being reclassified as promotional activity, which carries serious legal and regulatory consequences.
Before the meeting, invitations spell out the purpose, the advisory role each attendee will play, and the expected workload. The agenda leaves significant time for open discussion rather than presentations. Content must relate solely to the stated objective. If clinical data about a specific drug comes up, it should only be discussed when essential to meeting those objectives. Straying into product promotion, even subtly, can turn a legitimate advisory board into what regulators view as a disguised marketing event.
This distinction matters because advisory boards and speaker programs look similar on the surface (both involve paying doctors to talk about medicine) but serve fundamentally different purposes. A speaker program disseminates information the company already has. An advisory board collects information the company needs.
Who Gets Invited
Most advisory boards recruit key opinion leaders, often called KOLs. These are physicians or scientists with deep expertise in a therapeutic area, typically with strong publication records, leadership roles at medical congresses, or clinical experience that makes their perspective especially valuable. Many are academically driven and affiliated with major research institutions. Companies select them based on tiered criteria that weigh experience, specialty expertise, and relevance to the question at hand.
The selection process itself is a compliance consideration. Inviting a high-prescribing doctor who lacks relevant expertise looks like a reward for writing prescriptions, not a genuine search for insight. Companies document why each participant was chosen, linking their qualifications directly to the advisory board’s objectives.
Patient Advisory Boards
Not all advisory boards are filled with physicians. Patient advisory boards bring together people living with a condition, along with their caregivers and family members, to provide a different kind of input. These participants aren’t expected to have medical expertise. Instead, they share opinions based on personal experience: what it’s like to use a medication daily, how a clinical trial consent form reads to a non-specialist, whether a proposed pill bottle design actually works for someone with limited dexterity.
Companies use patient advisory boards to pressure-test protocol designs, clinical trial materials, technology platforms, and communication strategies. Recruitment often happens through patient advocacy groups or through ongoing relationships with individuals who’ve expressed interest in participating. The ideal group is small, typically no more than 10 people, with a deliberate mix of those who’ve participated in clinical trials before and those who haven’t. The format leans toward conversation rather than formal Q&A, structured as listening exercises where the company’s role is to absorb perspectives rather than steer them.
How Participants Are Compensated
Advisory board participants receive honoraria for their time, and calculating those payments is more complex than it might seem. Compensation must reflect fair market value, meaning it should match what someone with that level of expertise would reasonably be paid for comparable consulting work. Overpaying creates the appearance of inducement. Underpaying can signal the company doesn’t take the engagement seriously.
Fair market value is determined through structured models that classify experts into tiers based on experience, specialty, and credentials. These rates vary significantly by country, shaped by local currency strength, inflation, cost of labor, and the broader economic environment. A neurologist in Germany and a neurologist in Brazil with identical qualifications will have different fair market value rates because their local economies differ. Companies that operate globally build adjustment mechanisms into their compensation models to account for exchange rate fluctuations and cost of living changes, reducing the risk of payments that look out of step with local norms.
Transparency and Reporting Requirements
Advisory board payments don’t stay private. In the United States, the Physician Payments Sunshine Act requires manufacturers to report payments and transfers of value to the Centers for Medicare and Medicaid Services on an annual basis. This data, covering each full calendar year, becomes publicly searchable through the Open Payments database. Anyone can look up a specific doctor and see what companies paid them, including advisory board honoraria.
In Europe, the framework operates differently but with a similar goal. The EFPIA Disclosure Code requires member companies to publicly disclose transfers of value made to healthcare professionals, healthcare organizations, and patient organizations. This includes consultancy fees, advisory board payments, speaker fees, and sponsorship for attending medical meetings. Companies have been publishing this data since 2016.
One notable difference: European disclosure often depends on individual consent due to data protection laws. When a healthcare professional doesn’t consent to individual disclosure, the payment is reported in aggregate rather than attached to their name. If someone initially consents but later withdraws that consent, the company is obligated to remove their individual data from public view. In the US, no such consent mechanism exists. If a company pays a physician, the payment gets reported.
Why Companies Run Them
Advisory boards serve several practical purposes that internal teams can’t easily replicate. A company developing a new cancer drug might convene oncologists to understand how its trial endpoints align with what matters in real clinical practice. A team launching a product in a new country might gather local specialists to learn about prescribing habits, treatment guidelines, and healthcare system dynamics that differ from the home market. A medical affairs group working on a label expansion might ask rheumatologists how they currently manage a condition off-label and what evidence gaps prevent them from adopting a new approach.
The outputs vary. Some advisory boards produce recommendations that reshape clinical development strategy. Others generate insights that inform how a company communicates with regulators. Patient advisory boards frequently lead to concrete changes in trial design, such as simpler consent forms, fewer required site visits, or packaging modifications. What ties them together is that the company enters the room with a genuine question and leaves with input it plans to act on. When that standard slips, and the meeting becomes a vehicle for paying influential doctors or promoting a product under the guise of consultation, regulators and compliance teams treat it as a serious violation.